FOXO1 and Burkitt lymphoma: Gain-of-function mutations of CCND3 (5% of endemic BL and 38% of sporadic BL), which encodes for a D-type cyclin required for the proliferation of DZ B cells, and missense mutations of the FOXO1 transcription factor (20% of cases) are also recurrently found in different clinical variants of BL, highlighting a prominent oncogenic role for these two genes (69–73).